title: A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.
abstract: Although novel agents effective against malignant mesothelioma (MM) have been developed, the prognosis of patients with MM is still poor. We generated a DNA-chimeric siRNA against polo-like kinase-1 (PLK-1), which was more stable in human serum than the non-chimeric siRNA. The chimeric PLK-1 siRNA inhibited MM cell proliferation through the induction of apoptosis. Next, we investigated the effects of zoledronic acid (ZOL) on MM cells, and found that ZOL also induced apoptosis in MM cells. Furthermore, ZOL augmented the inhibitory effects of the PLK-1 siRNA. In conclusion, combining a PLK-1 siRNA with ZOL treatment is an attractive strategy against MM.
authors.affiliation: Department of Transfusion Medicine & Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Eri
authors.initials: E
authors.lastname: Kawata
authors.forename: Eishi
authors.initials: E
authors.lastname: Ashihara
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kiuchi
authors.forename: Mai
authors.initials: M
authors.lastname: Ogura
authors.forename: Hisayuku
authors.initials: H
authors.lastname: Yao
authors.forename: Kazuki
authors.initials: K
authors.lastname: Sakai
authors.forename: Ruriko
authors.initials: R
authors.lastname: Tanaka
authors.forename: Rina
authors.initials: R
authors.lastname: Nagao
authors.forename: Asumi
authors.initials: A
authors.lastname: Yokota
authors.forename: Miki
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Shinya
authors.initials: S
authors.lastname: Kimura
authors.forename: Hideyo
authors.initials: H
authors.lastname: Hirai
authors.forename: Taira
authors.initials: T
authors.lastname: Maekawa
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D048708:Cell Growth Processes / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002678:Chimera / Q000235:genetics; D003131:Combined Modality Therapy; D004247:DNA / Q000097:blood / Q000235:genetics*; D004164:Diphosphonates / Q000494:pharmacology*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008654:Mesothelioma / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000097:blood / Q000235:genetics; D014162:Transfection; D000077211:Zoledronic Acid; D000097869:Polo-Like Kinase 1
chemical_list: D018797:Cell Cycle Proteins; D004247:DNA; D004164:Diphosphonates; D007093:Imidazoles; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D000077211:Zoledronic Acid; D000097869:Polo-Like Kinase 1